Dichlorphenamide

Details

Stereochemistry	ACHIRAL
Molecular Formula	C6H6Cl2N2O4S2
Molecular Weight	305.159
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NS(=O)(=O)C1=CC(=C(Cl)C(Cl)=C1)S(N)(=O)=O

InChI

InChIKey=GJQPMPFPNINLKP-UHFFFAOYSA-N

InChI=1S/C6H6Cl2N2O4S2/c7-4-1-3(15(9,11)12)2-5(6(4)8)16(10,13)14/h1-2H,(H2,9,11,12)(H2,10,13,14)

HIDE SMILES / InChI

Molecular Formula	C6H6Cl2N2O4S2
Molecular Weight	305.159
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/011366s030lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.urmc.rochester.edu/news/story/4461/new-drug-for-periodic-paralysis-has-roots-in-urmc-research.aspx

Diclorphenamide, a carbonic anhydrase inhibitor, was initially developed for the treatment of glaucome, however, now it is used for patients suffering from primary hypokalemic and hyperkalemic periodic paralysis. The exact mechanism of diclorphenamide in periodic paralysis is unknown.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Carbonic anhydrase 6 Target ID: CHEMBL2095180 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/011366s030lbl.pdf	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Primary hyperkalemic periodic paralysis 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/011366s030lbl.pdf	Primary		Approved 8583	KEVEYIS Approved Use Keveyis is an oral carbonic anhydrase inhibitor indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants. Launch Date 1958
Primary hypokalemic periodic paralysis 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/011366s030lbl.pdf	Primary		Approved 8583	KEVEYIS Approved Use Keveyis is an oral carbonic anhydrase inhibitor indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants. Launch Date 1958

C_max

Value	Dose	Analyte	Population
3030 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29762909	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	DICHLORPHENAMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
709 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29762909	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	DICHLORPHENAMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1512 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29762909	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	DICHLORPHENAMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2219 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29762909	50 mg 2 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DICHLORPHENAMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
4867 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29762909	100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DICHLORPHENAMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
66456 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29762909	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	DICHLORPHENAMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
14734 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29762909	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	DICHLORPHENAMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
28901 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29762909	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	DICHLORPHENAMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
18329 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29762909	50 mg 2 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DICHLORPHENAMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
37468 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29762909	100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DICHLORPHENAMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
41 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29762909	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	DICHLORPHENAMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
51.4 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29762909	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	DICHLORPHENAMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
31.9 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29762909	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	DICHLORPHENAMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
12% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf			DICHLORPHENAMIDE plasma	Homo sapiens

Doses

Dose	Population	Adverse events
400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29762909	healthy, 38.1±12.1 Health Status: healthy Age Group: 38.1±12.1 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/29762909	Disc. AE: Hypokalemia, Weight loss... AEs leading to discontinuation/dose reduction: Hypokalemia (mild, 83.3%) Weight loss (16.7%) Itchy throat (16.7%) Tachycardia (16.7%) Gait instability (moderate, 16.7%) Toothache (moderate, 16.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/29762909
200 mg 1 times / day multiple, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2d4d6a8e-3122-4b91-b46a-5708e60ea5c1&type=display	unhealthy Health Status: unhealthy Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2d4d6a8e-3122-4b91-b46a-5708e60ea5c1&type=display	Disc. AE: Hypersensitivity, Hypokalemia... AEs leading to discontinuation/dose reduction: Hypersensitivity Hypokalemia Metabolic acidosis Fall Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2d4d6a8e-3122-4b91-b46a-5708e60ea5c1&type=display

AEs

AE	Significance	Dose	Population
Itchy throat	16.7% Disc. AE	400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29762909	healthy, 38.1±12.1 Health Status: healthy Age Group: 38.1±12.1 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/29762909
Tachycardia	16.7% Disc. AE	400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29762909	healthy, 38.1±12.1 Health Status: healthy Age Group: 38.1±12.1 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/29762909
Weight loss	16.7% Disc. AE	400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29762909	healthy, 38.1±12.1 Health Status: healthy Age Group: 38.1±12.1 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/29762909
Hypokalemia	mild, 83.3% Disc. AE	400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29762909	healthy, 38.1±12.1 Health Status: healthy Age Group: 38.1±12.1 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/29762909
Gait instability	moderate, 16.7% Disc. AE	400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29762909	healthy, 38.1±12.1 Health Status: healthy Age Group: 38.1±12.1 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/29762909
Toothache	moderate, 16.7% Disc. AE	400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29762909	healthy, 38.1±12.1 Health Status: healthy Age Group: 38.1±12.1 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/29762909
Fall	Disc. AE	200 mg 1 times / day multiple, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2d4d6a8e-3122-4b91-b46a-5708e60ea5c1&type=display	unhealthy Health Status: unhealthy Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2d4d6a8e-3122-4b91-b46a-5708e60ea5c1&type=display
Hypersensitivity	Disc. AE	200 mg 1 times / day multiple, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2d4d6a8e-3122-4b91-b46a-5708e60ea5c1&type=display	unhealthy Health Status: unhealthy Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2d4d6a8e-3122-4b91-b46a-5708e60ea5c1&type=display
Hypokalemia	Disc. AE	200 mg 1 times / day multiple, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2d4d6a8e-3122-4b91-b46a-5708e60ea5c1&type=display	unhealthy Health Status: unhealthy Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2d4d6a8e-3122-4b91-b46a-5708e60ea5c1&type=display
Metabolic acidosis	Disc. AE	200 mg 1 times / day multiple, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2d4d6a8e-3122-4b91-b46a-5708e60ea5c1&type=display	unhealthy Health Status: unhealthy Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2d4d6a8e-3122-4b91-b46a-5708e60ea5c1&type=display

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inhibitor 2252 inducer 1087	substrate 1193 inhibitor 2438	substrate 1388 inhibitor 2507

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OAT1 725 CYP1A2 2153 CYP2B6 926 CYP2C8 1057 CYP2C19 2057 P-gp 1741 BCRP 910 OATP1B1 1079 OATP1B3 961 OAT2 153 OAT4 150 OCT1 620 OCT2 779 MATE1 415 MATE2 267 OAT3 747	OAT1 395 OAT3 391 CYP1A2 1197 CYP2B6 776 CYP2C8 810 CYP2C19 1119 P-gp 2052 BCRP 697 OATP1B1 503 OATP1B3 435 OAT2 125 OAT4 93 OCT1 393 OCT2 434 MATE1 182 MATE2 98	CYP1A2 832 CYP2B6 669

Drug as perpetrator

Target	Modality	Activity
BCRP 985	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
CYP1A2 2333	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
CYP2B6 1160	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
CYP2B6 1160	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
CYP2C8 1117	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
CYP3A4 2633	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
MATE1 416	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
MATE2 267	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
OAT2 155	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
OAT3 749	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
OAT4 150	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
OATP1B1 1095	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
OATP1B3 970	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
OCT1 656	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
OCT2 782	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
OAT1 730	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 5.0	yes

Drug as victim

Target	Modality	Activity
BCRP 697	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
CYP1A2 1197	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 8.0	no
CYP2B6 776	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 8.0	no
CYP2C19 1119	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 8.0	no
CYP2C8 810	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 8.0	no
CYP2C9 1193	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 8.0	no
CYP2D6 1388	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 8.0	no
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 8.0	no
MATE1 182	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
MATE2 98	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
OAT2 125	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
OAT4 93	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
OATP1B1 503	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
OATP1B3 435	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
OCT1 393	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
OCT2 434	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
P-gp 2052	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
OAT1 395	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 6.0	yes
OAT3 391	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 6.0	yes

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY116256	https://www.001chemical.com/chem/120-97-8
3B Scientific (Wuhan) Corp	3B3-059238	http://www.3bsc.com/index/pro_info.php?id=98059
AA Blocks	AA000PYI	https://www.aablocks.com/goods/Goods/detail?id=AA000PYI
Aaron Chemicals	AR000QQA	http://www.aaronchem.com/120-97-8
abcr GmbH	AB547847	http://www.abcr.com/shop/en/AB547847
AbMole Bioscience	M3421	http://www.abmole.com/products/dichlorphenamide.html
Acadechem	ACDS-033119	http://www.acadechemical.com/product/107818
Achemtek	0104-042128	http://www.achemtek.com/120-97-8
Adooq BioScience	A10303	https://www.adooq.com/diclofenamide.html
AHH Chemical co.,ltd	MR-1005428	http://www.ahhchemical.com/product/MR-1005428.html
Alfa Chemistry	ACM120978	https://www.alfa-chemistry.com/dichlorphenamide-cas-120-97-8-item-285105.htm
Alfa Chemistry	AP120978	https://reagents.alfa-chemistry.com/product/dichlorphenamide-cas-120-97-8-2745.html
Ambeed	A201176	https://www.ambeed.com/products/120-97-8.html
Angel Pharmatech	AG193544	http://www.angelpharmatech.com/120-97-8.html
ApexBio Technology	A8408	http://www.apexbt.com/dichlorphenamide.html
BioChemPartner	BCP22591	http://www.biochempartner.com/120-97-8-BCP22591
BioCrick	BCC3761	http://www.biocrick.com/Dichlorphenamide-BCC3761.html
BioSynth	W-108466	https://www.biosynth.com/en/products/life-science/other-biochemicals/products/W-108466.html
BLD Pharm	BD124384	http://www.bldpharm.com/products/120-97-8.html
Boerchem	BC221062	http://www.boerchem.com/?product_37432.html
Capot Chemical	22279	http://www.capotchem.com/en/22279.htm
Capot Chemical	PubChem22279	http://www.capotchem.com/en/22279.htm
Chem Scene	CS-2491	http://www.chemscene.com/120-97-8.html
Chemenu	CM110408	http://www.chemenu.com/products/CM110408
ChemMol	44006581	http://www.chemmol.com/chemmol/44006581.html
ChemMol	49426554	http://www.chemmol.com/chemmol/49426554.html
Chemspace	CSSB00000058644	https://chem-space.com/CSSB00000058644
Clearsynth	CS-EB-00649	https://www.clearsynth.com/en/CSEB00649.html
Clearsynth	CS-ER-00637	https://www.clearsynth.com/en/CSER00637.html
Clearsynth	CS-O-00248	http://www.clearsynth.com/en/CSO00248.html
CSNpharm	CSN10791	https://www.csnpharm.com/products/dichlorphenamide.html
DC Chemicals	DCAPI1032	http://www.dcchemicals.com//product_show-Dichlorphenamide_Diclofenamide_.html
Excenen	EX-A1311	http://www.excenen.com/searchresultlist.php?id=120-97-8
Finetech	FT-0648264	http://www.finetechnology-ind.com/prod/detail/pub/120-97-8.html
Hairui	HR123582	http://www.hairuichem.com/en/product/120-97-8.html
iChemical	EBD45291	http://www.ichemical.com/chemicals/cas-120-97-8
Lab Network	LN01268499	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01268499
LGC Standards	LGCFOR1795.00	https://www.lgcstandards.com/US/en/p/LGCFOR1795.00
LGC Standards	MM1795.00	https://www.lgcstandards.com/US/en/p/MM1795.00
Matrix Scientific	144312	https://www.matrixscientific.com/144312.html
mcule	MCULE-4570158631	https://mcule.com/MCULE-4570158631/
MedChem Express	HY-B0397	https://www.medchemexpress.com/Dichlorphenamide.html
Molcore	MC116256	https://www.molcore.com/product/120-97-8
MuseChem	I000784	https://www.musechem.com/product/I000784.html
OChem	12091	http://www.ocheminc.com/index.php?act=psearch&pid=120D978
OChem	30668	http://www.ocheminc.com/index.php?act=psearch&pid=120D978
Sigma-Aldrich	1188006_USP	https://www.sigmaaldrich.com/catalog/product/usp/1188006?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech	S017462	http://www.sinfoobiotech.com/product/1020860
Smolecule	S525960	http://www.smolecule.com/products/s525960
THE BioTek	bt-267833	https://www.thebiotek.com/product/inhibitors/bt-267833
Yuhao Chemical	LL0492	http://www.chemyuhao.com/120-97-8.html

PubMed

Title	Date	PubMed
Increased expression of carbonic anhydrase I in the synovium of patients with ankylosing spondylitis.	2010-12-08	21143847
Evaluation of the therapeutic potential of carbonic anhydrase inhibitors in two animal models of dystrophin deficient muscular dystrophy.	2009-11-01	19648295
Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides.	2009-07-15	19520577
Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.	2009-05-14	19338333
Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.	2009-04-23	19317447
QSAR studies for the inhibition of the transmembrane carbonic anhydrase isozyme XIV with sulfonamides using PRECLAV software.	2009-04	18830873
Biodegradable fumarate-based drug-delivery systems for ophthalmic applications.	2009-03-15	18384171
Treatment of neuromuscular channelopathies: current concepts and future prospects.	2008-10	19019313
Carbonic anhydrase inhibitors. Sulfonamide diuretics revisited--old leads for new applications?	2008-07-21	18600270
Acetazolamide prevents vacuolar myopathy in skeletal muscle of K(+) -depleted rats.	2008-05	18345024
Practical aspects in the management of hypokalemic periodic paralysis.	2008-04-21	18426576
Treatment for periodic paralysis.	2008-01-23	18254068
Muscle channelopathies and electrophysiological approach.	2008-01	19966974
The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents.	2008	18336310
Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides.	2007-12-01	17826101
Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors.	2007-01-25	17228881
The development of topically acting carbonic anhydrase inhibitors as anti-glaucoma agents.	2007	17504129
Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.	2006-11-30	17125255
[Diuretic therapy in heart failure].	2006-04-25	16634001
Carbonic anhydrase inhibitors: cloning and sulfonamide inhibition studies of a carboxyterminal truncated alpha-carbonic anhydrase from Helicobacter pylori.	2006-04-15	16459077
Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs.	2006-03-23	16539401
Carbonic anhydrase inhibitors ameliorate the symptoms of hypokalaemic periodic paralysis in rats by opening the muscular Ca2+-activated-K+ channels.	2006-01	16368240
Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with benzo[b]thiophene 1,1-dioxide sulfonamides.	2005-11-01	16165351
Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides.	2005-09-01	16039848
Screening procedure for detection of diuretics and uricosurics and/or their metabolites in human urine using gas chromatography-mass spectrometry after extractive methylation.	2005-08	16044110
Expression of a novel carbonic anhydrase, CA XIII, in normal and neoplastic colorectal mucosa.	2005-04-18	15836783
[Diclofenamide].	2005-04-15	15871395
Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides.	2005-02-15	15686931
Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides.	2005-02-15	15686895
Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs?	2005-02-15	15686894
A Korean family of hypokalemic periodic paralysis with mutation in a voltage-gated calcium channel (R1239G).	2005-02	15716625
Theoretical study of gas-phase acidity, pKa, lipophilicity, and solubility of some biologically active sulfonamides.	2004-10-15	15388166
Carbonic anhydrase inhibitors. Inhibition of cytosolic isozyme XIII with aromatic and heterocyclic sulfonamides: a novel target for the drug design.	2004-07-16	15203157
Carbonic anhydrase inhibitors: the first QSAR study on inhibition of tumor-associated isoenzyme IX with aromatic and heterocyclic sulfonamides.	2004-06-21	15149691
Benzolamide is not a membrane-impermeant carbonic anhydrase inhibitor.	2004-06	15499999
Carbonic anhydrase inhibitors are specific openers of skeletal muscle BK channel of K+-deficient rats.	2004-04	14766795
Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the antipsychotic drug sulpiride.	2004-01-19	14698154
Carbonic anhydrase inhibitors: N-(p-sulfamoylphenyl)-alpha-D-glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits.	2004-01-05	14684332
Generation and evaluation of a CYP2C9 heteroactivation pharmacophore.	2003-12	14557374
Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogenosulfanilamide and halogenophenylaminobenzolamide derivatives.	2003-05-22	12747790
Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides.	2003-03-24	12643899
Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV.	2003-03-10	12617904
Long-term management of a glaucomatous eye in a dog treated with medical therapy alone.	2001-12	11789611
Randomized trials of dichlorphenamide in the periodic paralyses. Working Group on Periodic Paralysis.	2000-01	10632100
[Diclofenamide Reference Standard (Control 891) of National Institute of Hygienic Sciences].	1991	1364383
Carbonic anhydrase inhibitors and osmotic agents in glaucoma. Carbonic anhydrase inhibitors.	1968-08	5724852

Sample Use Guides

In Vivo Use Guide

Initial dose: 50 mg twice daily.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:03:42 GMT 2025` Edited by `admin` on `Mon Mar 31 18:03:42 GMT 2025`
Record UNII	VVJ6673MHY
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DICLOFENAMIDE

Preferred Name

English

Dichlorphenamide

Common Name

English

DICHLORPHENAMIDE [USP IMPURITY]

Common Name

English

diclofenamide [INN]

Common Name

English

DICLOFENAMIDE [JAN]

Common Name

English

DARANIDE

Brand Name

English

DICHLORPHENAMIDE [ORANGE BOOK]

Common Name

English

DICHLORPHENAMIDE [USP-RS]

Common Name

English

Diclofenamide [WHO-DD]

Common Name

English

DICHLORPHENAMIDE [MI]

Common Name

English

DICHLORPHENAMIDE [USP MONOGRAPH]

Common Name

English

DICHLORPHENAMIDE [HSDB]

Common Name

English

1,3-BENZENEDISULFONAMIDE, 4,5-DICHLORO-

Systematic Name

English

DICLOFENAMIDE [MART.]

Common Name

English

4,5-DICHLORO-M-BENZENEDISULFONAMIDE

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000175517